Methofill

Methotrexate, the active ingredient in Methofill, is an antimetabolite (folate antagonist) presented as an intravenous solution for intravenous use. It is employed in the management of certain cancers, autoimmune disorders, and ectopic pregnancy in adult patients.

GNH USA supplies Methofill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, ensuring quality and regulatory compliance.

Methotrexate acts on rapidly dividing cells and immune pathways, making it useful across several disease families. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: diminishes skin plaque formation and severity. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation. - Non‑Hodgkin lymphoma: impedes growth of lymphoma cells. - Ectopic pregnancy: terminates trophoblastic tissue to avoid surgical intervention.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring shortly after infusion. - Mucositis: inflammation and ulceration of the oral mucosa. - Fatigue: generalized tiredness during treatment cycles. - Elevated liver enzymes: mild transaminase rise detected on labs. - Myelosuppression: reduced white blood cell and platelet counts. - Dermatologic rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Pulmonary toxicity: interstitial pneumonitis presenting with cough and dyspnea. - Severe hepatotoxicity: marked liver injury requiring monitoring. - Renal failure: acute kidney injury due to precipitation of drug crystals. - Severe bone marrow suppression: pancytopenia with infection risk. - Neurotoxicity: seizures or encephalopathy in high‑dose settings. - Anaphylaxis: rare hypersensitivity reaction requiring immediate medical attention.

Methofill requires careful monitoring and patient education before and during therapy. - Pregnancy: contraindicated; teratogenic risk is classified as Category X. - Renal function: assess creatinine clearance; dose adjustment may be needed. - Hepatic function: monitor liver enzymes regularly; avoid in severe hepatic impairment. - Hematologic status: perform complete blood counts before each dose. - Concomitant folate: supplement with folic acid to reduce mucosal toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methofill can interact with several drug classes, altering efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Proton pump inhibitors: may elevate methotrexate serum levels. - Penicillins (high‑dose): reduce renal clearance, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Sulfonamides: additive bone‑marrow suppression. - Azathioprine or mycophenolate: enhanced immunosuppression. - Live vaccines: risk of infection due to immunosuppression. - Trimethoprim‑sulfamethoxazole: increased myelosuppression. - Vitamin B12 or folic acid supplements: may lessen therapeutic effect if excessive.